Business Context and Reporting Period
Company: Omeros Corp
Filing Type: Form 8-K (Current Report)
Date of Report: March 13, 2012
Reporting Period: Single event date (March 13, 2012)
Omeros Corp, a biopharmaceutical company incorporated in Washington, filed this report to disclose the announcement of results from a Phase 3 clinical trial for its drug candidate OMS302. The trial evaluated the drug in patients undergoing intraocular lens replacement surgery.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The material change reported is the completion and announcement of results for the Phase 3 clinical trial of OMS302. No financial changes or comparisons to prior periods are included in this document.
Guidance, Outlook, and Risks
Management Commentary: The company issued a press release (Exhibit 99.1) detailing the trial results, which is incorporated by reference. The filing itself contains no specific text regarding the outcome of the trial, future guidance, or management outlook beyond the announcement of the event.
Risks and Contingencies: No specific risks or contingencies are detailed in the body of this 8-K filing.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for the specific statistical results and conclusions of the OMS302 Phase 3 trial.
- Verify the impact of the trial results on the company's regulatory pathway and potential market approval.
- Check subsequent filings (e.g., 10-Q or 10-K) for financial impacts related to the trial completion or any changes in cash burn rate.